



GLOBAL JOURNAL OF MEDICAL RESEARCH

Volume 12 Issue 10 Version 1.0 Year 2012

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 Print ISSN:0975-5888

## The Possible Clinical Beneficial Effects of Atorvastatin in Iraqi Patients with Systolic Heart Failure

By Dr. Masar Samir Baker, Prof. Dr. Kassim Al-Shamma & Dr. Mohammed Noori Al-dujaili

*Department of clinical pharmacy, faculty of pharmacy, Al-Kufa university*

**Abstract** - This study was designed to evaluate the therapeutic effectiveness of atorvastatin in Iraqi patients with systolic heart failure. Sixty heart failure patients were participated in this study and their ages ranged from (35-72) years. The patients were divided into three groups: patients with heart failure and normal lipid profile not receiving atorvastatin (group one), patients with heart failure and normal lipid profile receiving atorvastatin (group two), patients with heart failure and dyslipidemia receiving atorvastatin. Twenty healthy subjects were selected to be a normal group for the purpose of comparison. Several parameters of inflammation and oxidative stress (hs-CRP, TNF- $\alpha$ , total antioxidant status and adiponectin) as well as left ventricular ejection fraction were measured. The study duration was three months and the parameters were measured at baseline, one-half month and three months. The results showed that the serum level of hs- CRP, TNF- $\alpha$  and total antioxidant status were not significantly changed in group one patients, while they were significantly changed in the other two groups.

**Keywords** : atorvastatin, heart failure, high sensitivity-C reactive protein, tumor necrosis factor- $\alpha$ , adiponectin, total antioxidant status, left ventricular ejection fraction.

**GJMR-L Classification** : NLMC Code: WG 120



*Strictly as per the compliance and regulations of :*



© 2012 Dr. Masar Samir Baker, Prof. Dr. Kassim Al-Shamma & Dr. Mohammed Noori Al-dujaili. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# The Possible Clinical Beneficial Effects of Atorvastatin in Iraqi Patients with Systolic Heart Failure

Dr. Masar Samir Baker <sup>α</sup>, Prof. Dr. Kassim Al-Shamma <sup>σ</sup> & Dr. mohammed Noori Al-dujaili <sup>ρ</sup>

**Abstract** - This study was designed to evaluate the therapeutic effectiveness of atorvastatin in Iraqi patients with systolic heart failure. Sixty heart failure patients were participated in this study and their ages ranged from (35-72) years. The patients were divided into three groups: patients with heart failure and normal lipid profile not receiving atorvastatin (group one), patients with heart failure and normal lipid profile receiving atorvastatin (group two), patients with heart failure and dyslipidemia receiving atorvastatin. Twenty healthy subjects were selected to be a normal group for the purpose of comparison. Several parameters of inflammation and oxidative stress (hs-CRP, TNF- $\alpha$ , total antioxidant status and adiponectin) as well as left ventricular ejection fraction were measured. The study duration was three months and the parameters were measured at baseline, one-half month and three months. The results showed that the serum level of hs-CRP, TNF- $\alpha$  and total antioxidant status were not significantly changed in group one patients, while they were significantly changed in the other two groups. The serum level of adiponectin was not significantly changed in any of the three groups. The LVEF was significantly increased in the two groups who received atorvastatin, while it was not significantly changed in group one patients.

**Keywords :** atorvastatin, heart failure, high sensitivity-C reactive protein, tumor necrosis factor- $\alpha$ , adiponectin, total antioxidant status, left ventricular ejection fraction.

## I. INTRODUCTION

Congestive heart failure (CHF) is a complex clinical syndrome that can result from any functional or structural cardiac disorder that impairs the ventricle's ability to fill with or eject blood<sup>(1)</sup>. The treatment and prevention of HF has become a burgeoning public health problem reaching epidemic levels.

Especially for the elderly population<sup>(2)</sup>. Because of the high mortality rate associated with CHF, it is important to identify modifiable risk factors and develop effective strategies for the prevention of CHF in the general population. Results of prospective cohort studies have indicated that old age, male sex, hypertension, diabetes, obesity, valvular heart disease,

and CHD are important risk factors for CHF<sup>(3)</sup>. There are only a limited number of ways in which the function of the heart can be affected. The most common causes of functional deterioration of the heart are damage or loss of heart muscle, acute or chronic ischaemia, increased vascular resistance with hypertension, or the development of a tachyarrhythmia such as atrial fibrillation<sup>(4)</sup>. In heart failure, the cardiac reserve is largely maintained through compensatory or adaptive mechanisms such as the Frank-Starling mechanism; activation of neurohumoral influences such as the sympathetic nervous system, the renin-angiotensin-aldosterone mechanism, natriuretic peptides, and locally produced vasoactive substances; and myocardial hypertrophy and remodeling<sup>(5)</sup>. Persistent inflammation, involving increased levels of inflammatory cytokines, seems to play a pathogenic role in chronic heart failure (HF) by influencing heart contractility, inducing hypertrophy and promoting apoptosis, contributing to myocardial remodeling<sup>(6)</sup>. An increasing body of evidence suggests that oxidative stress is involved in the pathogenesis of a wide range of cardiovascular diseases, including hypertension, Type II diabetes, hypercholesterolaemia, atherosclerosis and heart failure<sup>(7)</sup>. Diastolic heart failure (DHF) and systolic heart failure (SHF) are 2 clinical subsets of the syndrome of heart failure that are most frequently encountered in clinical practice<sup>(8)</sup>. The New York Heart Association (NYHA) developed a functional classification for patients with heart disease<sup>(9)</sup> table (1.1). Heart failure is a clinical syndrome that may be difficult for a primary care physician to diagnose accurately, particularly if the symptoms develop slowly and are not so severe as to warrant immediate hospitalization<sup>(10)</sup>. Fatigue, dyspnoea and peripheral oedema are typical symptoms and signs of heart failure, but not necessarily specific<sup>(11)</sup>. Echocardiography is vital in evaluating patients with known or suspected HF<sup>(12)</sup>. A large number of high quality trials on pharmacological therapy have been undertaken in patients with left ventricular systolic dysfunction with all stages of disease from asymptomatic left ventricular systolic dysfunction to severe heart failure. The aims of treatment are to prevent progression of the disease, thereby reducing symptoms, hospital admissions and mortality<sup>(13)</sup>. The beneficial role of statins in HF may be explained by its anti-

**Author  $\alpha$  :** Department of clinical pharmacy, faculty of pharmacy, Al-Kufa university. E-mail : pharm\_masar@yahoo.com

**Author  $\sigma$  :** Department of clinical pharmacy, faculty of pharmacy, Baghdad university.

**Author  $\rho$  :** Faculty of medicine, Al-Kufa university.

inflammatory effects<sup>(14)</sup>. According to the cytokine hypothesis, HF progresses because cytokines exacerbate haemodynamic abnormalitie or exert direct toxic effects on the heart<sup>(15)</sup>. Cardiomyocyte loss by apoptosis has been recognized as a potential cause of heart failure .The prevention of cardiomyocyte apoptosis may be a part of the protective mechanisms of statins against heart failure<sup>(16)</sup>.

## II. SUBJECTS & METHODS

### a) Patients

This study was carried out at Al-Sadr medical city in Al-Najaf governorate from November 2011 until August 2012. Sixty male patients completed the course of atorvastatin for three months successfully. All patients were previously diagnosed with systolic heart failure and receiving the traditional anti failure treatment. Some of those patients (group one and group two) have normal lipid profile, while patients in group three have dyslipidemia. All patients did not receive any lipid lowering treatment (statin). Their age ranged from (35-72) years.

*Patients were divided as follows :*

*Group one :* Twenty patients with congestive heart failure and normal lipid profile on placebo.

*Group two :* Twenty patients with congestive heart failure and normal lipid profile treated with atorvastatin 40 mg once daily.

*Group three :* Twenty patients with congestive heart failure and dyslipidemia treated with atorvastatin 40 mg once daily.

### b) Healthy Subjects

Twenty subjects who were apparently healthy selected for the purpose of comparison. These subjects were selected from the medical staff and some relative volunteers. All of them were males. Their ages ranged from (-) years.

### c) Exclusion Criteria

- Dyslipidemia (group one and group two).
- Previous statin treatment.
- Diabetes mellitus.
- Ischemic heart disease.
- Female.

### d) Sample Collection And Preparation

A blood sample (10) was collected by vene puncture used a sterile disposable syringe in a plane plastic tube from each of the healthy subjects and patient after fasting overnight , and left at room temperature for 30 minutes for clotting , then centrifuged at 3000 rpm for 10 minutes.

*Serum was taken by micropipette and divided into 2 parts:*

1. The first part was send to the hospital laboratory for lipid profile.

2. The second part was subdivided into 4 parts and stored at (-20C)to be used in other tests (hs-CRP, TNF- $\alpha$ , total antioxidant status and adiponectin).

### e) Statistical Analysis

All data were expressed as mean  $\pm$  standard error means (SEM). Statistical analyses were carried out using paired t-test, independent t-test and one way annovato compare between mean values of parameters. P value < 0.05 was considered statistically significant. Descriptive analysis was carried out by SPSS16 software.

## III. RESULTS

### a) The effect of atorvastatin on lipid profile parameters (TC, TG, HDL-C, LDL-C, VLDL-C) in patients with heart failure

#### i. Group one

Table 2. shows the lipid profile parameters of group one patients who have heart failure with normal lipid profile, they did not receive atorvastatin therapy. Comparison is also made with control group.

In regard to total cholesterol (TC), the table showed that there is significant difference between the pretreatment value of heart failure patients and healthy individuals. However , the pretreatment value is within the normal range in the literature.

The other lipid profile parameters values of this group (TG, HDL-C, LDL-C, VLDL-C) also are significantly different from the control group.

Within the group, comparison is made among the three visits during the three months follow up duration (pretreatment, one half month, three months).

This table showed that the first visit values of TC and HDL-C are not significantly changed from the pretreatment values, while they are significantly different for TG, LDL-C and VLDL-C.

All lipid profile parameters (TC, TG, HDL-C, LDL-C and VLDL-C) readings after three months did not significantly changed from the previous values.

#### ii. Group two

Table 3. showed a comparison between pretreatment values of all lipid profile parameters (TC, TG, HDL-C, LDL-C and VLDL-C) in group two patients, who complain from heart failure with normal lipid and receiving atorvastatin therapy, and control group.

This table shows a significant difference in all lipid profile parameters (TC, TG, HDL-C, LDL-C and VLDL-C) between pretreatment values of grouptwo and healthy individuals in control group. Another comparison is made between the three visits during the follow up duration for this group.

After one-half month follow up, all lipid profile parameters (TC, TG, HDL-C, LDL-C and VLDL-C) are significantly different from pretreatment values.

After three months treatment with atorvastatin, the results showed further significant lowering of all lipid

profile parameters (TC, TG, HDL-C, LDL-C and VLDL-C) from the previous follow up visit.

### iii. Group three

Table 4. includes a comparison of lipid profile parameters (TC, TG, HDL-C, LDL-C and VLDL-C) between pretreatment values of group three patients who complain from heart failure and dyslipidemia, they received atorvastatin treatment.

The results showed that all lipid profile parameters are significantly different between retreatment values of this group and healthy individuals in control group. All lipid profile parameters in group three patients are significantly changed after one-half month treatment with atorvastatin.

At the end of follow up duration, the lipid profile parameters are significantly changed as compared with mid-duration values.

### b) *Serum level of hs-CRP, TNF- $\alpha$ , adiponectin and total antioxidant status and ejection fraction of group one (patients with heart failure and normal lipid profile not treated with atorvastatin), group two (patients with heart failure and normal lipid profile treated with atorvastatin), group three (patients with heart failure and dyslipidemia treated with atorvastatin) and control group.*

Table 5. showed a comparison between pretreatment values of all biomarkers and ejection fraction with healthy individuals in control group. The pretreatment values of hs-CRP, TNF- $\alpha$ , adiponectin and total antioxidant status are significantly different from control group.

There is a significant difference in pretreatment value of hs-CRP and TNF- $\alpha$  between group one and group three.

For adiponectin, there is a significant difference in pretreatment values between group one and group two, also a significant difference is shown between group two and group three.

Regarding to ejection fraction, the pretreatment value of each group is significantly different from control group patients.

### c) *The effect of atorvastatin on the serum level of hs-CRP in patients with heart failure*

Table 6. showed that there is no significant change in serum level of hs-CRP in group one patients who have heart failure and normal lipid profile and not receiving atorvastatin therapy neither after one-half month nor after three months.

While in group two patients who have heart failure and normal lipid profile and receiving atorvastatin therapy, there is a significant lowering in serum level of hs-CRP after one-half month and three months.

For dyslipidemic patients in group three who complain from heart failure and receiving atorvastatin

therapy, there is a significant lowering in serum level of hs-CRP after one-half month and three months.

If comparison is made between the three groups, we see that there is a significant difference between group one in side and group two and group three in other side in the serum level of hs-CRP in the mid and last readings.

### d) *The effect of atorvastatin on the serum level of TNF- $\alpha$ in patients with heart failure*

Table 7. showed a comparison among the three readings of serum TNF- $\alpha$  in group one patients who complain from heart failure, but they have normal lipid profile and not receiving atorvastatin therapy.

The results showed that there is no significant change in serum level of TNF- $\alpha$  after one-half month and after three months.

In group two patients who have heart failure and normal lipid profile and receiving atorvastatin treatment, we see that there is a significant lowering in the serum level of TNF- $\alpha$  after one-half month and three months of treatment.

The results of group three patients who are dyslipidemic and have heart failure and receiving atorvastatin therapy showed that there is a significant change in the serum level of TNF- $\alpha$  after one-half month and three months of therapy.

### e) *The effect of atorvastatin on the serum level of adiponectin in patients with heart failure*

Table 8. showed the results of serum adiponectin in three group patients.

Group one who have heart failure and normal lipid profile and not receiving atorvastatin therapy, group two who have heart failure and normal lipid profile and receiving atorvastatin and group three who are dyslipidemic and have heart failure and receiving atorvastatin therapy.

In all groups, there is no significant change in adiponectin values neither after one-half month nor after three months.

It is evident from the table that there is significant difference in the adiponectin value between group one and group two in side and group two and group three in other side.

### f) *The effect of atorvastatin on the serum level of total antioxidant status in patients with heart failure*

Table 9. compare the serum levels of total antioxidant status among the three visits during the follow up duration.

The results showed that in group one who have heart failure and normal lipid profile and not receiving atorvastatin therapy, there is no significant change in the serum level of total antioxidant status after the treatment duration was completed.

While in group two patients who have the same criteria but receiving atorvastatin therapy, a significant change in the serum level of total antioxidant status is noted after one-half month and three months.

Group three patients who are dyslipidemic and have heart failure and receiving atorvastatin therapy, the results showed that there is significant change in the serum level of total antioxidant status in the mid and end of therapy duration.

There is a significant difference in the serum level of total antioxidant status between group one who did not receive atorvastatin therapy and group two who receive the therapy for three months.

#### g) *The effect of atorvastatin on the ejection fraction in patients with heart failure*

Table 10. showed a comparison in the ejection fraction among the three groups.

As we see, in group one, there is no significant change in ejection fraction after the complement of treatment duration.

While in group two who receive atorvastatin therapy, there is a significant increase in ejection fraction in the mid and end of treatment duration.

In group three who receive the atorvastatin therapy, there is also a significant increase in ejection fraction after one-half month and three months of therapy.

A significant difference is noted between group one in side and group two and group three in other side in the value of ejection fraction.

## IV. DISCUSSION

The last decade has witnessed major advances in the understanding of the molecular mechanisms of HF in response to stress signals. A multitude of extracellular factors and signaling pathways are involved in altering transcriptional regulatory networks controlling cardiac adaptation or maladaptation, and the transition to overt HF<sup>(17)</sup>. The recognition of the dismal prognosis of heart failure has led to greater efforts to identify the condition early and to optimize risk stratification strategies to guide management<sup>(18)</sup>. It is becoming increasingly apparent that inflammatory mediators play a crucial role in the development of CHF, and several strategies to counterbalance different aspects of the inflammatory response are considered<sup>(19)</sup>.

The inflammatory cytokines playing a direct role in worsening HF through the induction of myocyte apoptosis, ventricular dilation, and endothelial dysfunction<sup>(20)</sup>. In table 2. which shows the lipid profile parameters of group one patients who have heart failure and normal lipid profile and not receiving atorvastatin therapy, we see that the serum level of total cholesterol, high density lipoprotein cholesterol and low density lipoprotein are not significantly changed at the end of

treatment duration, while the serum level of triglyceride and very low density lipoprotein cholesterol are significantly decreased in the mid duration of therapy.

In table 3. which shows the lipid profile of group two who have heart failure and normal lipid profile and receiving atorvastatin therapy, we see that all lipid profile parameters are significantly changed in the mid and end of treatment duration.

All lipid profile parameters for group three who are dyslipidemic and have heart failure are significantly changed after one-half month and three months of atorvastatin therapy, as shown in table 4.

Atorvastatin reduces total-C, LDL-C, VLDL-C, apo B, and TG, and increases HDL-C in patients with hypercholesterolemia and mixed dyslipidemia. Therapeutic response is seen within 2 weeks, and maximum response is usually achieved within 4 weeks and maintained during chronic therapy<sup>(21)</sup>.

Fasting lipid profile must be assessed in patients with heart failure, the goal of LDL-C is <100 mg/dL (primary goal) or <70 mg/dL (optional goal).

Other possible beneficial effects of statins in CHF patients are also supported. Statin use was associated with improved event-free survival in congestive heart failure patients. Thus, statin treatment in heart failure patients appears promising<sup>(22)</sup>.

Table 5. showed the following:

- *Patients suffering from heart failure (group one, group two and group three) have significantly higher serum levels of hs-CRP as compared with control group.*

In control group the serum level of hs-CRP is 0.74 mg/L, while they are 11.62, 10.41 and 8.95 for group one, group two and group three respectively.

Elevated levels of the inflammatory marker high-sensitivity C-reactive protein (hs-CRP) are associated with increased risk for CVD<sup>(23,24)</sup>.

Higher hsCRP concentrations occurred in patients with higher New York Heart Association functional class and were related to higher rates of readmission and mortality<sup>(25)</sup>.

Guidelines for use of hsCRP as an adjunct to global risk prediction, even when levels of LDL-C are low, were issued by the American Heart Association in 2003, and risk algorithms incorporating hsCRP such as the Reynolds Risk Score have been developed and validated<sup>(26)</sup>.

- *Patients suffering from heart failure (group one, group two and group three) have significantly higher serum levels of TNF- $\alpha$  as compared with control group.*

The serum level of TNF- $\alpha$  in control group patients is 14.63 pg/ml, while they are 40.93, 35.56 and 34.46 for group one, group two and group three respectively.

Chronic heart failure patients have high circulating levels of TNF $\alpha$ , which correlate with the severity of their disease. TNF $\alpha$  has several deleterious effects, including myocardial cell apoptosis, blunted beta-adrenergic signaling, fetal gene activation, endothelial dysfunction, and collagen production. These processes lead to cellular breakdown, decreased cardiac contractility and enhancement of the remodeling process. Moreover, in patients with advanced heart failure, TNF $\alpha$  is associated with cardiac cachexia and rennin-angiotensin system activation and is an independent predictor of mortality<sup>(27,28)</sup>.

Accumulating evidence suggests that the inflammatory cytokine TNF (tumour necrosis factor)- $\alpha$  plays a pivotal role in the disruption of macrovascular and microvascular circulation both in vivo and in vitro<sup>(29)</sup>.

- *Patients suffering from heart failure (group one, group two and group three) have significantly higher serum levels of adiponectin as compared with control group.*

For control group patients, the serum adiponectin level is 7.4 mg/L, while they are 16.58, 12.36 and 18.39 for group one, group two and group three respectively.

Surprisingly, high adiponectin levels in CHF patients are associated with an increased mortality risk and not with lower risk<sup>(30)</sup>. Serum adiponectin concentrations were stratified according to NYHA class. The more advanced the CHF was (according to NYHA class), the higher the adiponectin concentrations were<sup>(31)</sup>. It has been suggested that adiponectin predicts mortality and morbidity in HF patients. Given the vaso- and cardioprotective properties of adiponectin, these findings cannot be easily explained, and cachexia seems to be the connective link: the reduction in body mass may up-regulate adiponectin's synthesis. As it has been suggested, adiponectin raised levels may just reflect the hyper-catabolic state in severe HF<sup>(32)</sup>.

Contrary to other adipose-derived hormones, adiponectin concentrations are reduced in subjects with coronary heart diseases, obesity, insulin resistance, or type 2 diabetes<sup>(33)</sup>.

A number of clinical studies showed a decrease of adiponectin levels in obese humans relative to lean subjects. Plasma adiponectin levels were decreased in diabetic as compared to non-diabetic individuals. Other studies found an inverse relationship between plasma adiponectin and serum triglyceride levels as well as fasting and postprandial plasma glucose concentrations<sup>(34)</sup>.

All these factors and others results in a big variation in serum adiponectin level among the three groups.

- *Patients in all three groups have significantly lower serum level of total antioxidant status as compared with control group.*

The serum level of total antioxidant status in control group patients is 1.74, while they are 1.104, 1.053 and 0.966 in group one, group two and group three respectively.

Although the biological mechanisms for progression and ventricular remodeling have yet to be definitively explained, mounting evidence supports the theory that ventricular dysfunction worsens as a consequence of increased reactive oxygen species (ROS) formation<sup>(35)</sup>.

- *All three groups have significantly lower ejection fraction as compared with control group patients.*

The ejection fraction in control group is 68.34, while the pretreatment values are 31.43, 33.02 and 30.29 for group one, group two and group three respectively.

Ejection fraction is an useful hemodynamic parameter, that is not always indicative of left ventricular function concerning the peripheral perfusion.

In systolic HF, the primary defect is an impaired ability of the heart to contract. The myocardium is weakened, and the resultant impairment of contractility leads to reduced cardiac output. In addition, systolic HF usually shows an E.F.% < 50% and is associated with eccentric left ventricular hypertrophy<sup>(36)</sup>.

The 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) have been unequivocally shown to reduce cardiovascular morbidity and mortality. Their lipid-lowering actions are by reversible and competitive inhibition of the enzyme HMG-CoA reductase, a precursor of cholesterol. It has been suggested that statins appear to have therapeutic benefits in diseases that are unrelated to elevated serum cholesterol levels<sup>(37)</sup>.

This is further evidenced by studies showing that statins may improve cardiovascular performance even in subjects without overt hyperlipidaemia<sup>(38,39)</sup>.

Table 6. showed the effect of atorvastatin on the serum level of hs-CRP of the three groups.

In group one the serum level of hs-CRP is not significantly changed after three months of follow up.

While in group two the serum level is significantly decreased from 10.41, 5.51 to 4.1 (mg/L) at the pretreatment, one-half month and three months respectively.

The results of group three patients also showed a significant decrease in the serum level of hs-CRP in the mid and end of therapy duration.

The serum level of hs-CRP is decreased from 8.95, 5.48 to 4.51 (mg/L) at the pretreatment, one-half month and three months respectively.

Patients who have lower hsCRP levels after statin therapy have better clinical outcomes regardless of the resultant level of LDL. Reduction in LDL and hsCRP are independent indicators of the success of statins in reducing cardiovascular risk<sup>(40)</sup>.

The observations that statins therapy reduces serum hsCRP and that serum hsCRP is correlated with cardiovascular risk raises the possibility that the risk reduction with statin therapy may be attributed, at least in part, to antiinflammatory effects<sup>(41,42)</sup>.

Atorvastatin are among the most widely used Statins in the world. In addition to lowering serum cholesterol, Atorvastatin lowers CRP, an index of inflammation<sup>(43,44)</sup>.

C-reactive protein has been shown to exert direct adverse effects on the vascular endothelium by reducing nitric-oxide release and increasing endothelin-1 production, as well as by inducing expression of endothelial adhesion molecules. These findings suggest that C-reactive protein may also play a causal role in vascular disease and could therefore be a target of therapy<sup>(45)</sup>.

It is very difficult to argue not to add hs-CRP measurements to our patient global risk assessment and Framingham CHD risk scores especially in those with two risk factors or strong family history. Patients with high CRP/LDL are in the highest risk category and should be treated, including statins<sup>(46)</sup>.

Table 7. showed the effect of atorvastatin on the serum level of TNF- $\alpha$  of the three groups.

In group one the serum level of TNF- $\alpha$  is not significantly changed after three months of follow up.

While in group two the serum level is significantly decreased from 35.56, 30.16 to 28.8 (pg/ml) at the pretreatment, one-half month and three months respectively.

The results of group three patients also showed a significant decrease in the serum level of TNF- $\alpha$  in the mid and end of therapy duration.

The serum level of TNF- $\alpha$  is decreased from 34.46, 30.28 to 26.51 (pg/ml) at the pretreatment, one-half month and three months respectively.

TNF- $\alpha$  is increased in CHF and seems to reflect the severity of the disease (Levine et al., 1990; Testa et al., 1996; Torre et al., 1996). It has been shown that TNF- $\alpha$  is of prognostic value as there is a relation between the level of TNF- $\alpha$  and mortality (Torre et al., 1996; Rauchhaus et al., 2000). It has been suggested that the strongest prognosticator in the TNF- $\alpha$  system is the soluble TNF receptor 1 (Rauchhaus et al., 2000). It has furthermore been shown that TNF- $\alpha$  is increased especially in cachectic ;[CHF patients (Parissis et al., 1999)<sup>(47)</sup>.

A large number of studies have shown the beneficial effects of statins with regards to markers of inflammation including TNF- $\alpha$  (tumour necrosis factor- $\alpha$ ). Overactivity of the immune system has been a matter of ongoing concern in patients with HF for almost two decades now, and, in particular, TNF- $\alpha$  and its soluble receptors have been demonstrated to be markers of an adverse prognosis in patients with this disease (48).

Treatment with atorvastatin markedly ameliorated LV remodelling and LV function and reduced the levels of TNF- $\alpha$ <sup>(49)</sup>.

Table 8. showed the serum levels of adiponectin in all three groups.

The serum level of adiponectin is not significantly changed in anyone of the three groups after the complement of the study duration.

Recently, Qu et al. reported that rosuvastatin but not atorvastatin increased serum adiponectin levels in patients with hypercholesterolaemia, which is consistent with our finding in patients with congestive heart failure<sup>(50)</sup>.

Thus, the potential beneficial effects of statins on adiponectin level may appear less detectable. In addition, some of our patients were hypertensive and they were receiving treatment that may potentially influence the insulin sensitivity<sup>(51)</sup>.

These factors, combined with the smaller number of our study population, may confound our results. This possible adiponectin-lowering effect of statins warrants elucidation in larger homogenous population.

Table 9. showed the effect of atorvastatin on the serum level of total antioxidant status in the three groups patients.

In group one patients, there is no significant change in the serum level of total antioxidant status at the end of study duration.

In group two, as we saw in the table, the serum level of total antioxidant status is significantly increased after one-half month and three months of treatment with atorvastatin.

It is increased from 1.053, 1.934 to 2 at the pretreatment, one-half month and three months respectively.

In group three patients, there is also a significant increase in the serum level of total antioxidant status at the mid and end of treatment duration.

It is increased from 0.966, 1.783 to 1.908 at pretreatment, one-half month and three months respectively.

Statins, in addition to improving lipid profiles, may also lower oxidative stress<sup>(52)</sup>.

Studies showed that oxidized low density lipoprotein (LDL) is a major correlate of oxidative stress in hypercholesterolemic patients and that statins may reduce oxidative stress by reducing enhanced plasma levels of LDL, which are more susceptible to peroxidation in hypercholesterolemia, and change the LDL structure, making them more resistant to peroxidation.

Some studies further showed that statins may also inhibit NAD(P)H oxidase, thus decreasing the generation of reactive oxygen species (ROS), thereby adding or synergizing the biological effects of antioxidants.

Some studies also showed that statins or their metabolites may act as antioxidants, directly or indirectly by removing "aged LDL", which is more prone to oxidation, from the circulation.

Based on these findings, it is evident that among their properties, statins also possess antioxidant activities<sup>(53,54,55)</sup>.

Table 10. showed the effect of atorvastatin on ejection fraction in all three groups.

In group one patients, the ejection fraction is not significantly increased at the end of study duration.

In group two patients, the ejection fraction is significantly increased at the mid and end of treatment duration.

It is increased from 33.02, 35.02 to 38.68 at the pretreatment, one-half month and three months respectively.

A significant increase in ejection fraction is also seen in group three patients.

It is increased from 30.29, 35.31 to 37.96 at the pretreatment, one-half month and three months interval respectively.

Accurate and reproducible determination of left ventricular (LV) function is essential for the diagnosis, disease stratification, therapeutic guidance, follow-up and estimation of prognosis for the majority of cardiac diseases<sup>(56)</sup>.

Notably, Atorvastatin treatment significantly suppressed the signs of HF and the number of cardiac myocytes was greatly reduced<sup>(57)</sup>.

The administration of atorvastatin was found to improve left ventricular ejection fraction, attenuated adverse left ventricular remodeling in patients with non-ischemic HF<sup>(58)</sup>.

## V. CONCLUSIONS

- Atorvastatin 40 mg tablet is beneficial in normalizing lipid profile parameters in dyslipidemic patients.
- Atorvastatin is effective in attenuating the inflammatory process which is associated with bad prognosis in congestive heart failure. This effectiveness is recorded through the measurement of the serum level of hs-CRP and TNF- $\alpha$ .
- This treatment is also effective in increasing antioxidant, thus delaying the worsening in heart failure because oxidative stress is directly associated with the bad prognosis process occurring in heart failure.
- Atorvastatin increases the ejection fraction in patients with established heart failure and this may alleviate some of the signs and symptoms associated with heart failure.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Michael S Figueroa MD and Jay I Peters MD FAARC (2006). Congestive Heart Failure: Diagnosis, Pathophysiology, Therapy, and Implications for Respiratory Care. RESPIRATORY CAREVOL 51 NO 4.
2. M. Yamani and B.M. Massie, Congestive heart failure: insights from epidemiology, implications for treatment. Mayo ClinProc68 (1993), pp. 1214–1218.\*
3. Jiang He, MD, PhD; Lorraine G. Ogden, MS; Lydia A. Bazzano, PhD; Suma Vupputuri, MPH; Catherine Loria, PhD, MS; Paul K. Whelton, MD, MSc (2001). Risk Factors for Congestive Heart Failure in US Men and Women. ARCH INTERN MED/VOL 161.
4. Kenneth Dickstein (Chairperson) (Norway), Alain Cohen-Solal (France), et al. (2008). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal29, 2388–2442.
5. Carol porth (2007). Essentials of pathophysiology. UNIT VI Cardiovascular Function, CHAPTER 28 Heart Failure and Circulatory Shock.
6. PAL AUKRUST1, LARS GULLESTAD, THOR UELAND, JAN K. DAMA, ARNE YNDESTAD (2005). Inflammatory and anti-inflammatory cytokines in chronic heart failure: Potential therapeutic implications. Annals of Medicine37: 74–85.
7. Carlene A. HAMILTON, William H. MILLER, Sammy AL-BENNA, M. Julia BROSNAN, Russell D. DRUMMOND, Martin W. MCBRIDE and Anna F. DOMINICZAK (2004). Strategies to reduce oxidative stress in cardiovascular disease. Clinical Science 106, 219–234.
8. KANU CHATTERJEE, MB, FRCP, FCCP, FACC, FAHA, MACP, AND BARRY MASSIE, MD, FACC (2007). Systolic and Diastolic Heart Failure: Differences and Similarities. Journal of Cardiac Failure Vol. 13 No. 7.
9. Kim Sutherland (2010). Bridging the quality gap: Heart failure. The Health Foundation978-1-906461-18-8.
10. F D R Hobbs,1 J Doust,2 J Mant,3 M R Cowie (2012). Diagnosis of heart failure in primary care. Education in Heart96:1773-777.
11. Sticares, Cardiovascular Research Foundation, P.O. Box 882, 3160 AB, Rhon, The Netherlands, Department of Medicine, Gothenburg University, Sahlgrenska University Hospital, SE-416 85 Gothenburg, Sweden (2002). Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Journal of Heart Failure 4 11-22 European Society of Cardiology.
12. Rosemary Browne, MD; Barry Weiss, MD (2010). A Resource for Interprofessional Providers Heart Failure Diagnosis. ELDER CARE(520) 626-5800.
13. Scottish Intercollegiate Guidelines Network (2007). Management of chronic heart failure. www.sign.ac.uk
14. Marcio Hiroshi Miname, Raul D. Santos, Neusa Forti,

- Jayne Diamant (2007). Are Statins Beneficial in Heart Failure?. Point of View 738 – 04107-031.
15. Maciej Banach<sup>1</sup>, Jarosław Drożdż, Piotr Okonski<sup>1</sup> and Jacek Rysz (2005). Immunological Aspects of the Statins' Function in Patients with Heart Failure: A Report from the Annual Conference of ESC –Heart Failure 2005. Cellular & Molecular Immunology Volume 2 Number 6.
  16. Elsevier B.V. (2003). Statins for heart failure: a potential for new treatment. Cardiovascular Research 60 217– 219.
  17. Carsten Skurk<sup>1</sup>, Frank Wittchen, Lennart Suckau<sup>1</sup>, Henning Witt, Michael Noutsias, Henry Fechner, Heinz-Peter Schultheiss, and Wolfgang Poller (2008). Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. European Heart Journal 29, 1168–1180.
  18. Douglas S. Leea and Ramachandran S. Vasana (2005). Novel markers for heart failure diagnosis and prognosis. Current Opinion in Cardiology, 20:201–210.
  19. Stefan D Anker, Stephan von Haehling (2004). INFLAMMATORY MEDIATORS IN CHRONIC HEART FAILURE: AN OVERVIEW. Heart ;90:464–470.
  20. Benjamin M. Scirica, Christopher P. Cannon, Marc S. Sabatine, Petr Jarolim, Sarah Sloane, Nader Rifai, Eugene Braunwald, and David A. Morrow (2009). Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death. Clinical Chemistry 55:2265–273.
  21. Lea Andrew P and McTavish D. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs 1997; 53(5): 828 – 47.
  22. Michael Christ, Theresia Klima, Wolfram Grimm, Hans-Helge Mueller, and Bernhard Maisch (2006). Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. European Heart Journal 27, 691–699.
  23. Ulrich Kintscher (2007). Does adiponectin resistance exist in chronic heart failure?. European Heart Journal 28, 1676–1677.
  24. Ishwarlal Jialal, MD, PhD, FRCPATH, and Sridevi Devaraj, PhD (2001). Inflammation and Atherosclerosis The Value of the High-Sensitivity C-Reactive Protein Assay as a Risk Marker. American Society of Clinical Pathologists 116 (Suppl 1):S108–S115.
  25. Paul O. Collinson (2009). Concentrations of C-Reactive Protein and B-Type Natriuretic Peptide 30 Days after Acute Coronary Syndromes Independently Predict Hospitalization for Heart Failure and Cardiovascular Death: Just Another Brick in the Wall?. Clinical Chemistry 55:2 203–205.
  26. Paul M Ridker (2008). The Time for Cardiovascular Inflammation Reduction Trials Has Arrived : How Low to go for hs-CRP. Arterioscler Thromb Vasc Biol. 2008;28:1222-1224.
  27. Offer Amir MD<sup>1</sup>, Ori Rogowski MD, Miriam David PhD, Nitza Lahat PhD, Rafael Wolff MD and Basil S. Lewis MD FRCP (2010). Circulating Interleukin-10: Association with Higher Mortality in Systolic Heart Failure Patients with Elevated Tumor Necrosis Factor-Alpha. IMAJ • VOL 12.
  28. Dimitris Tousoulis<sup>T</sup>, Charalambos Antoniades, Carmen Vassiliadou, Marina Toutouza, Christos Pitsavos, Costas Tentolouris, Athanasios Trikas, Christodoulos Stefanadis (2005). Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. The European Journal of Heart Failure 7 1126 – 1132.
  29. Hanrui ZHANG, Yoonjung PARK, Junxi WU, Xiu ping CHEN, Sewon LEE, Jiyeon YANG, Kevin C. DELLSPERGER and Cuihua ZHA (2009). Role of TNF- $\alpha$  in vascular dysfunction. Clinical Science 116, 219–230.
  30. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756–1762.
  31. Roxana SISU, MD (2006). Adiponectin concentrations in patients with congestive heart failure. A Journal of Clinical Medicine, Volume 1 No.4.
  32. C. Antoniades, A. S. Antonopoulos, D. Tousoulis and C. Stefanadis (2009). Adiponectin: from obesity to cardiovascular disease. obesity reviews 10, 269–279.
  33. Tobias Pischon, Cynthia J Girman, Nader Rifai, Gokhan S Hotamisligil, and Eric B Rimm (2012). Association between dietary factors and plasma adiponectin concentrations in men. American Society for Clinical Nutrition; 81:780–6.
  34. M. HALUZÍK, J. PAŘÍZKOVÁ, M.M. HALUZÍK (2004). Adiponectin and Its Role in the Obesity-Induced Insulin Resistance and Related Complications. Physiol. Res. 53: 123-129.
  35. Joshua M. Hare (2001). Oxidative Stress and Apoptosis in Heart Failure Progression. Circ Res. ;89:198-200.
  36. Federico Cacciapuoti (2010). Are Clinical Heart Failure and Ejection Fraction Always Connected?. Open Heart Failure Journal, 3, 1-8.
  37. Khayatnouri Mirhadi (2012). Effect of Different Doses of Pravastatin on Formalin-Induced

- Inflammatory Response in Mice. *Global Veterinaria* 8 (6): 636-641.
38. Charalambos Vlachopoulos, Konstantinos Aznaouridis, Anna Dacre, Carmen Vasiliadou, Constantina Masoura, Elli Stefanadi, John Skoumas, Christos Pitsavos, and Christodoulos Stefanadis (2007). Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. *European Heart Journal* 28, 2102–2109.
  39. Trinath K Mishra (2008). Role of Statins in Heart Failure. *JIACM* ; 9(2): 108-14.
  40. THOZHUKATSATHYAPALAN, MD, MRCP STEPHEN L. ATKIN, FRCP, PHD ERIC S. KILPATRICK, MD, FRCPATH, FRCP(E)D (2010). Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes. *DIABETES CARE*, VOLUME 33, NUMBER 9.
  41. Ruth S. Weinstock, MD, PhD,\* Ronald B. Goldberg, MD, John R. Guyton, MD, Theodore Mazzone, MD, Adam Polis, MA, Joanne E. Tomassini, PhD, Jianxin Lin, MS, Arvind Shah, PhD, Andrew M. Tershakovec, MD, MPH (2008). Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. *Journal of Clinical Lipidology* 2, 25–35.
  42. IshwarlalJialal, MD, PhD, FRC Path, and SrideviDevaraj, PhD (2001). The Value of the High-Sensitivity C-Reactive Protein Assay as a Risk Marker. *Am J Clin Pathol* ;116 (Suppl 1):S108-S115.
  43. Sarana Boonbaichaiyapruk MD, Sayan Cheepudomwit MD, Pradit Panjavenin MD, Taworn Suthichaiyakul MD, Worachart Moleelerkpoom MD, Thanawat Benjanuwatra MD, Bancha Sukanandachai MD, Adisai Buakhamsri MD (2008). Effect of Atorvastatin on LDL & hs-CRP in a Selected Thai Population. *J Med Assoc Thai* ; 91 (8): 1189-95.
  44. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes-The Strong Heart Study. *Circulation*. 2005;112:1289–1295.
  45. Eugene Braunwald, M.D. (2008). Biomarkers in Heart Failure. *N Engl J Med* ;358:2148-59.
  46. Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. NCEP-ATP III (CHD Risk Calculator). *JAMA* May 16 2001; 285: 2486-97.
  47. Andreas Kjör and Birger Hesse (2001). Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. *Clinical Physiology* 21, 6, 661-672.
  48. Stephan VON HAEHLING (2009). Statins for heart failure: still caught in no man's land?. *Clinical Science* 116, 37–39.
  49. Christian STUMPF, Sebastian PETZI, Katrin SEYBOLD, Gerald WASMEIER, Martin ARNOLD, Dorette RAAZ, Atilla YILMAZ, Werner G. DANIEL and Christoph D. GARLICH (2009). Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. *Clinical Science* 116, 45–52.
  50. Takayoshi Tsutamato, Masayuki Yamaji, Chiho Kawahara, Keizo Nishiyama, Masanori Fujii, Takashi Yamamoto, and Minoru Horie (2009). Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. *European Journal of Heart Failure* 11, 1195–1201.
  51. Philip Yu-An Ding, Pai-Feng Hsu and Tse-Min Lu (2009). Statin Therapy on Insulin Resistance and Plasma Level of Adiponectin in Non-Diabetic, Hypercholesterolemic Patients. *Acta Cardiol Sin*;25:183-9.
  52. Carlene A. HAMILTON, William H. MILLER, Sammy AL-BENNA, M. Julia BROSNAN, Russell D. DRUMMOND, Martin W. MCBRIDE and Anna F. DOMINICZAK (2004). Strategies to reduce oxidative stress in cardiovascular disease. *Clinical Science* 106, 219–234.
  53. MOHAMMAD A. NASAR<sup>1</sup>, ABDALLAJARRARI<sup>1</sup>, MOHAMMAD A. NASEER, TARANNUM F. SUBHANI, BEENA V. SHETTY and FAIYAZ SHAKEEL (2009). Antioxidant status of atorvastatin in hypercholesterolemic patients. *J. Serb. Chem. Soc.* 74 (10) 1063–1073.
  54. DAYUAN LI, HONGJIANG CHEN, FRANCESCO ROMEO, TATSUYA SAWAMURA, TOM SALDEEN, and JAWAHAR L. MEHTA (2002). Statins Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1. *Vol. 302, No. 2* 34959/991282.
  55. Steven J. Miller (2001). Emerging mechanisms for secondary cardioprotective effects of statins. *Cardiovascular Research* 52, 5–7.
  56. S-M KO, MD, Y-J KIM, MD, J-H PARK, MD and N-M CHOI, MD (2010). Assessment of left ventricular ejection fraction and regional wall motion with 64-slice multidetector CT: a comparison with two-dimensional transthoracic echocardiography. *The British Journal of Radiology*, 83, 28–34.
  57. Xian Jing Song, Chun Yan Yang, Bin Liu, Qun Wei<sup>1</sup>, Melvin T. Korkor<sup>1</sup>, Jie Yu Liu, Ping Yang (2011). Atorvastatin Inhibits Myocardial Cell Apoptosis in a Rat Model with Post-myocardial Infarction Heart Failure by Downregulating ER Stress Response. *International Journal of Medical Sciences*; 8(7):564-572.
  58. Sola S, MirMQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. *J Am Coll Cardiol*. 2006; 47: 332-7.

Table (1.1) : NYHA classes of CHF.

| Limitations on Physical Activity | Symptoms with Ordinary Physical Activity             | Status at Rest      | Class |
|----------------------------------|------------------------------------------------------|---------------------|-------|
| none                             | none                                                 | comfortable         | I     |
| slight                           | symptomatic with ordinary activities                 | comfortable         | II    |
| marked                           | symptomatic at less than ordinary levels of activity | comfortable         | III   |
| unable to perform any activity   | discomfort with any activity                         | symptomatic at rest | IV    |

Table (3.2) : Lipid profile (TC, TG, HDL-C, LDL-C, VLDL-C) in group one (patients with heart failure and normal lipid profile not treated with atorvastatin) and control group (healthy individuals). Values are presented as mean±standard error. Number of patients in this group is 20.

| LIPID PROFILE PARAMETER | CONTROL GROUP | PRETREATMENT | ONE AND HALF MONTH AFTER TREATMENT | THREE MONTHS AFTER TREATMENT |
|-------------------------|---------------|--------------|------------------------------------|------------------------------|
| TC<br>mg/dl             | 107.21±6.03   | 142.73±2.34* | 141.27±3.91                        | 139.4±3.82                   |
| TG<br>mg/dl             | 88.43±5.01    | 127.07±3.82* | 111.0±4.0 <sup>a</sup>             | 112.6±3.01                   |
| HDL-C<br>mg/dl          | 57.57±0.93    | 50.33±1.51*  | 48.73±1.57                         | 49.53±1.53                   |
| LDL-C<br>mg/dl          | 31.95±4.09    | 66.99±1.98*  | 70.34±1.54 <sup>a</sup>            | 67.35±1.69                   |
| VLDL-C<br>mg/dl         | 17.69±1.0     | 25.41±0.76*  | 22.2±0.8 <sup>a</sup>              | 22.52±0.6                    |

\*significant at  $P < 0.05$  as compared with control group.

<sup>a</sup> significant at  $P < 0.05$  as compared with pretreatment.

TC: total cholesterol, TG: triglyceride, HDL\_C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, VLDL-C: very low density lipoprotein cholesterol.

**Table (3.3) :** Lipid profile (TC, TG, HDL-C, LDL-C, VLDL-C) in group two (patients with heart failure and normal lipid profile treated with atorvastatin) and control group. Values are presented as mean±standard error. Number of patients in this group is 20.

| LIPID PROFILE<br>PARAMETER | CONTROL GROUP | PRETREATMENT | ONE AND HALF<br>MONTH AFTER<br>TREATMENT | THREE MONTHS<br>AFTER<br>TREATMENT |
|----------------------------|---------------|--------------|------------------------------------------|------------------------------------|
| TC<br>mg/dl                | 107.21±6.03   | 153.73±4.38* | 147.07±4.89 <sup>a</sup>                 | 119.13±5.64 <sup>b</sup>           |
| TG<br>mg/dl                | 88.43±5.01    | 107.79±5.41* | 90.79±6.88 <sup>a</sup>                  | 80.68±3.33 <sup>b</sup>            |
| HDL-C<br>mg/dl             | 57.57±0.93    | 49.26±1.59*  | 52.4±1.93 <sup>a</sup>                   | 55.27±1.06 <sup>b</sup>            |
| LDL-C<br>mg/dl             | 31.95±4.09    | 82.91±1.71*  | 76.51±1.56 <sup>a</sup>                  | 47.72±3.91 <sup>b</sup>            |
| VLDL-C<br>mg/dl            | 17.69±1.0     | 21.55±1.08*  | 18.16±1.38 <sup>a</sup>                  | 16.14±0.67 <sup>b</sup>            |

\*significant at  $P<0.05$  as compared with control group.

a significant at  $P<0.05$  as compared with pretreatment.

b significant at  $P<0.05$  as compared with one and half month.

TC: total cholesterol, TG: triglyceride, HDL-C: lipoprotein cholesterol, VLDL-C: very low density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol.

**Table (3.4) :** Lipid profile (TC, TG, HDL-C, LDL-C, VLDL-C) in group three (patients with heart failure and dyslipidemia treated with atorvastatin) and control group. Values are presented as mean±standard error. Number of patients in this group is 20.

| LIPID PROFILE<br>PARAMETER | CONTROL GROUP | PRETREATMENT | ONE AND HALF<br>MONTH AFTER<br>TREATMENT | THREE MONTHS<br>AFTER<br>TREATMENT |
|----------------------------|---------------|--------------|------------------------------------------|------------------------------------|
| TC                         | 107.21±6.03   | 225.33±6.77* | 162.0±9.75 <sup>a</sup>                  | 137.33±5.57 <sup>b</sup>           |
| TG                         | 88.43±5.01    | 204.07±8.82* | 163.93±7.31 <sup>a</sup>                 | 130.0±6.69 <sup>b</sup>            |
| HDL-C                      | 57.57±0.93    | 35.47±0.8*   | 41.53±0.89 <sup>a</sup>                  | 49.2±0.73 <sup>b</sup>             |
| LDL-C                      | 31.95±4.09    | 149.05±4.21* | 87.68±3.79 <sup>a</sup>                  | 62.13±3.5 <sup>b</sup>             |
| VLDL-C                     | 17.69±1.0     | 40.81±1.76*  | 32.79±1.46 <sup>a</sup>                  | 26.0±1.34 <sup>b</sup>             |

\*significant at  $P<0.05$  as compared with control group.

a significant at  $P<0.05$  as compared with pretreatment.

b significant at  $P<0.05$  as compared with one and half month.

**Table (3.5) :** Serum levels of pretreatment hs-CRP, TNF- $\alpha$ , adiponectin and total antioxidant status and ejection fraction of group one (patients with heart failure and normal lipid profile not treated with atorvastatin), group two (patients with heart failure and normal lipid profile treated with atorvastatin), group three (patients with heart failure and dyslipidemia treated with atorvastatin) and control group. Values are presented as mean $\pm$ standard error. Number of patients in each group is 20.

| PARAMETER             | CONTROL GROUP    | GROUP ONE          | GROUP TWO                      | GROUP THREE                    |
|-----------------------|------------------|--------------------|--------------------------------|--------------------------------|
| hs-CRP(mg/L)          | 0.74 $\pm$ 0.08  | 11.62 $\pm$ 0.46*  | 10.41 $\pm$ 0.56*              | 8.95 $\pm$ 0.61* <sup>a</sup>  |
| TNF- $\alpha$ (pg/ml) | 14.63 $\pm$ 1.35 | 40.93 $\pm$ 3.53*  | 35.56 $\pm$ 1.02*              | 34.46 $\pm$ 1.10* <sup>a</sup> |
| Adipnctin(mg/L)       | 7.4 $\pm$ 0.69   | 16.58 $\pm$ 0.93*  | 12.36 $\pm$ 0.64* <sup>a</sup> | 18.39 $\pm$ 2.19* <sup>b</sup> |
| TAS (mmol/L)          | 1.74 $\pm$ 0.091 | 1.104 $\pm$ 0.037* | 1.053 $\pm$ 0.077*             | 0.966 $\pm$ 0.042*             |
| EF%                   | 68.34 $\pm$ 2.19 | 31.43 $\pm$ 0.29*  | 33.02 $\pm$ 0.58*              | 30.29 $\pm$ 0.45* <sup>b</sup> |

\*significant at  $P<0.05$  as compared with control group.

a significant at  $P<0.05$  as compared with group one.

b significant at  $P<0.05$  as compared with group two.

hs-CRP: high sensitivity c-reactive protein, TNF- $\alpha$ : tumor necrosis factor- $\alpha$ , TAS: total antioxidant status, EF: ejection fraction.

**Table (3.6) :** Serum hs-CRP (mg/L) in group one (patients with heart failure and normal lipid profile not treated with atorvastatin), group two (patients with heart failure and normal lipid profile treated with atorvastatin) and group three (patients with heart failure and dyslipidemia treated with atorvastatin). Values are presented as mean $\pm$ standard error. Number of patients is 20 in each group.

| GROUP                    | PRETREATMENT     | ONE AND HALF MONTH AFTER TREATMENT | THREE MONTHS AFTER TREATMENT  |
|--------------------------|------------------|------------------------------------|-------------------------------|
| Group one hs-CRP(mg/L)   | 11.62 $\pm$ 0.46 | 10.71 $\pm$ 0.35                   | 10.63 $\pm$ 0.81              |
| Group two hs-CRP(mg/L)   | 10.41 $\pm$ 0.56 | 5.51 $\pm$ 0.3* <sup>a</sup>       | 4.1 $\pm$ 0.21* <sup>a</sup>  |
| Group three hs-CRP(mg/L) | 8.95 $\pm$ 0.61  | 5.48 $\pm$ 0.39* <sup>a</sup>      | 4.51 $\pm$ 0.26* <sup>a</sup> |

\*Significant at  $P<0.05$  as compared with pretreatment.

a Significant at  $P<0.05$  as compared with group one.

**Table (3.7) :** Serum TNF- $\alpha$  (pg/mL) in group one (patients with heart failure and normal lipid profile not treated with atorvastatin), group two (patients with heart failure and normal lipid profile treated with atorvastatin) and group three (patients with heart failure and dyslipidemia treated with atorvastatin). Values are presented as mean $\pm$ standard error. Number of patients is 20 in each group.

| GROUP                                | PRETREATMENT     | ONE AND HALF MONTH AFTER TREATMENT | THREE MONTHS AFTER TREATMENT  |
|--------------------------------------|------------------|------------------------------------|-------------------------------|
| Group one<br>TNF- $\alpha$ (pg/ml)   | 40.93 $\pm$ 3.53 | 38.28 $\pm$ 0.85                   | 38.51 $\pm$ 0.72              |
| Group two<br>TNF- $\alpha$ (pg/ml)   | 35.56 $\pm$ 1.02 | 30.16 $\pm$ 0.89 <sup>*a</sup>     | 28.8 $\pm$ 0.73 <sup>*a</sup> |
| Group three<br>TNF- $\alpha$ (pg/ml) | 34.46 $\pm$ 1.10 | 30.28 $\pm$ 1.21 <sup>*a</sup>     | 26.51 $\pm$ 1.4 <sup>*a</sup> |

*\*significant at  $P < 0.05$  as compared with pretreatment.*

*a significant at  $P < 0.05$  as compared with group one.*

**Table (3.8) :** Serum adiponectin (mg/L) in group one (patients with heart failure and normal lipid profile not treated with atorvastatin), group two (patients with heart failure and normal lipid profile treated with atorvastatin) and group three (patients with heart failure and dyslipidemia treated with atorvastatin). Values are presented as mean $\pm$ standard error. Number of patients is 20 in each group.

| GROUP                            | PRETREATMENT                   | ONE AND HALF MONTH AFTER TREATMENT | THREE MONTHS AFTER TREATMENT   |
|----------------------------------|--------------------------------|------------------------------------|--------------------------------|
| Group one<br>Adiponectin(mg/L)   | 16.58 $\pm$ 0.93               | 16.55 $\pm$ 0.99                   | 16.14 $\pm$ 0.94               |
| Group two<br>Adiponectin(mg/L)   | 12.36 $\pm$ 0.64 <sup>ab</sup> | 12.45 $\pm$ 0.65 <sup>ab</sup>     | 12.29 $\pm$ 0.53 <sup>ab</sup> |
| Group three<br>Adiponectin(mg/L) | 18.39 $\pm$ 2.19               | 18.67 $\pm$ 2.09                   | 18.2 $\pm$ 1.98                |

*a significant at  $P < 0.05$  as compared with group one.*

*b significant at  $P < 0.05$  as compared with group three.*

**Table (3.9) :** Serum total antioxidant status (mmol/L) in group one (patients with heart failure and normal lipid profile not treated with atorvastatin), group two (patients with heart failure and normal lipid profile treated with atorvastatin) and group three (patients with heart failure and dyslipidemia treated with atorvastatin). Values are presented as mean $\pm$ standard error. Number of patients is 20 in each group.

| GROUP                      | PRETREATMENT      | ONE AND HALF MONTH AFTER TREATMENT | THREE MONTHS AFTER TREATMENT   |
|----------------------------|-------------------|------------------------------------|--------------------------------|
| Group one<br>TAS(mmol/L)   | 1.104 $\pm$ 0.037 | 1.056 $\pm$ 0.034                  | 1.026 $\pm$ 0.033              |
| Group two<br>TAS(mmol/L)   | 1.053 $\pm$ 0.077 | 1.934 $\pm$ 0.017 <sup>*a</sup>    | 2.0 $\pm$ 0.011 <sup>*a</sup>  |
| Group three<br>TAS(mmol/L) | 0.966 $\pm$ 0.042 | 1.783 $\pm$ 0.019 <sup>*b</sup>    | 1.908 $\pm$ 0.028 <sup>*</sup> |

*\*significant at P<0.05 as compared with pretreatment.*

*a significant at P<0.05 as compared with group one.*

*b significant at P<0.05 as compared with group two.*

**Table (3.10) :** Ejection fraction in group one (patients with heart failure and normal lipid profile not treated with atorvastatin), group two (patients with heart failure and normal lipid profile treated with atorvastatin) and group three (patients with heart failure and dyslipidemia treated with atorvastatin). Values are presented as mean $\pm$ standard error. Number of patients is 20 in each group.

| GROUP              | PRETREATMENT     | ONE AND HALF MONTH AFTER TREATMENT | THREE MONTHS AFTER TREATMENT   |
|--------------------|------------------|------------------------------------|--------------------------------|
| Group one<br>EF%   | 31.43 $\pm$ 0.29 | 32.71 $\pm$ 0.13                   | 30.63 $\pm$ 0.33               |
| Group two<br>EF%   | 33.02 $\pm$ 0.58 | 35.06 $\pm$ 0.7 <sup>*a</sup>      | 38.68 $\pm$ 0.32 <sup>*a</sup> |
| Group three<br>EF% | 30.29 $\pm$ 0.45 | 35.31 $\pm$ 0.49 <sup>*a</sup>     | 37.96 $\pm$ 0.51 <sup>*a</sup> |

*\*significant at P<0.05 as compared with pretreatment.*

*a significant at P<0.05 as compared with group one.*